Vascarta's Topical Curcumin Gel VAS-101 Shows Significant Pain Reduction in Knee Osteoarthritis Phase 1b Trial
核心洞察
Vascarta (搜索)'s VAS-101 topical curcumin gel demonstrated statistically significant reductions in knee pain compared to placebo in a 60-patient Phase 1b trial published in Frontiers in Pain Research.
The study showed 39.3% of VAS-101 participants reported feeling "much improved" or "very much improved" compared to 13.3% in the placebo group, with significant improvements in KOOS pain scores.
VAS-101 was well tolerated with no significant adverse reactions, and Vascarta (搜索) plans to file an Investigational New Drug Application with the FDA later this year.
Vascarta Inc (搜索). announced positive results from a randomized, double-blind, placebo-controlled Phase 1b clinical trial evaluating VAS-101, its investigational topical/transdermal curcumin gel for knee osteoarthritis pain. The study, published in Frontiers in Pain Research, demonstrated statistically significant pain reduction and improved quality of life outcomes compared to placebo.
Clinical Trial Design and Methodology
The trial enrolled 60 adults aged 45-75 with knee osteoarthritis who applied either 0.1 mL VAS-101 or 0.1 mL placebo gel to the affected knee every other day for 28 days. Researchers assessed outcomes using validated measures including the KOOS pain subscale as the primary endpoint, daily pain ratings, performance-based physical function tests, and use of rescue oral pain medication.
Significant Pain Reduction Outcomes
VAS-101 produced meaningful improvements across multiple pain measures. The treatment group showed significant improvement in KOOS pain score (β: 5.12; 95% CI: 0.47–9.77; p = 0.041) and significant reduction in daily pain ratings (p = 0.005). Notably, 39.3% of participants using VAS-101 reported feeling "much improved" or "very much improved," compared with 13.3% in the placebo group (p = 0.019).
The study also found that 32.1% of participants achieved a Minimal Clinically Important Difference in symptoms, compared with 13.3% with placebo, indicating clinically meaningful benefits for a substantial portion of patients.
Safety Profile and Tolerability
VAS-101 demonstrated a favorable safety profile with no significant adverse reactions reported. The only observed side effect was temporary skin staining, a known characteristic of topical curcumin, which resolved within two to three days after discontinuation.
Clinical Significance and Expert Commentary
Dr. Adrian Lopresti, Managing Director of Clinical Trials Australia and principal investigator, stated, "The results of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants. VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis."
Joel Friedman, M.D., Ph.D., inventor of Vascarta (搜索)'s patented transdermal drug delivery technology and Chief Scientific Officer, noted, "While further research with larger patient populations and longer treatment durations is needed, these findings highlight the potential role of VAS-101 in managing osteoarthritis pain."
Regulatory and Development Plans
Chairman and CEO Richard Prince, Ph.D. emphasized the clinical potential, stating, "These data indicate the potential of VAS-101 to become the standard of care in osteoarthritis. We intend to accelerate our efforts in the development of VAS-101 for osteoarthritis with the anticipated filing of an Investigational New Drug Application to the United States Food & Drug Administration later this year."
Novel Transdermal Delivery Approach
VAS-101 represents a novel approach to curcumin delivery, utilizing Vascarta (搜索)'s proprietary transdermal technology to deliver the compound through the skin directly into affected joints. This method potentially provides localized and enhanced systemic anti-inflammatory and analgesic effects while bypassing the gastrointestinal tract and first-pass liver metabolism that may limit oral curcumin formulations.
The positive Phase 1b results position VAS-101 as a potential non-oral therapeutic option for managing osteoarthritis-related knee pain, addressing limitations associated with current oral formulations in this patient population.